This work aimed to evaluate the metabolic and atherogenic effects of long-term antiepileptic drugs in a group of Egyptian epileptic patients. Sixty-nine epileptic patients on antiepileptic drug monotherapy for at least 2 years and 34 control subjects were recruited in this study. Patients were divided into 5 subgroups according to antiepileptic drugs used (valproate, carbamazepine, lamotrigine, topiramate, and levetiracetam). Fasting lipid profile (total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol), lipoprotein(a), homocysteine, free thyroxine, thyroid-stimulating hormone, and common carotid artery intima-media thickness were measured for all subjects. Significant higher mean values of low-density lipoprotein cholesterol, low-density lipoprotein / high-density lipoprotein ratio, lipoprotein(a), homocysteine, significantly lower mean value of high-density lipoprotein cholesterol, and significantly larger diameter of common carotid artery intima-media thickness were observed in each drug-treated group versus control group. Our study supports that long-term monotherapy treatment with valproate, carbamazepine, lamotrigine, and topiramate had altered markers of vascular risk that might enhance atherosclerosis, whereas levetiracetam exerted minimal effect.
KhotSSShaikhHLalitkumarG. Atherosclerotic risk among Epileptic patients taking carbamazepine, phenytoin treatment: a brief review. Int J Pharm Sci Res. 2013;4:900–906.
2.
KarceskiSC. Advances in managing epilepsy. Patients Care. 2005;39:29–67.
3.
HasanEMMomtazOMAboul-FotohLE. Lipid profile and carotid intima-media thickness as predictors for early atherosclerosis in epileptic children. Egypt J Neurol Psychiatr Neurosurg. 2013;50:55–59.
4.
Lopinto-KhouryCMintzerS. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol. 2010;12:300–308.
5.
HamedSAHamedEAHamdyRNabeshimaT. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res. 2007;74:183–192.
6.
ChuangYCChuangHYLinTK. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012;53:120–128.
7.
LacerdaGCB. Treating seizures in renal and hepatic failure. J Epilepsy Clin Neurophysiol. 2008;14(suppl 2):46–50.
8.
ÜnalÖDedaGTeberS. Thrombotic risk factors in epileptic children treated with valproic acid. Pediatr Neurol. 2009;40:102–106.
9.
MintzerSSkidmoreCTAbidinCJ. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol. 2009;65:448–456.
10.
PrakashPrabhuLVNasarM A. Lamotrigine in pregnancy: safety profile and the risk of malformations. Singapore Med J. 2007;48:880–883.
11.
FranzoniEVerrottiASarajlijaJ. Topiramate: effects on serum lipids and lipoproteins levels in children. Eur J Neurol. 2007;14:1334–1337.
12.
BelcastroVStrianoP. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res. 2012;102:1–7.
13.
IsojärviJITPakarinenAJMyllyläVV. Thyroid function with antiepileptic drugs. Epilepsia. 1992;33:142–148.
14.
JakubusTMichalska-JakubusMLukawskiK. Atherosclerotic risk among children taking antiepileptic drugs. Pharmacol Rep. 2009;61:411–423.
15.
AttilakosAAGaroufiAVoudrisK. Thyroid dysfunction associated with increased low-density lipoprotein cholesterol in epileptic children treated with carbamazepine monotherapy: a causal relationship?Eur J Paediatr Neurol. 2007;11:358–361.
16.
GhajarzadehMBorjiSPourjabbarS. Nonalcoholic fatty liver disease, carotid intima-media thickness and lipid profile in epileptic children. J Neurol Res. 2011;1:105–108.
17.
TanTYLuCHChuangHY. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia. 2009;50:1579–1586.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
20.
National Cholesterol Education Program (NCEP): highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992;89:495–501.
21.
WaltonKWHitchensJMagnaniHNKhanM. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis. 1974;20:323–346.
22.
RaitakariOTAdamsMRCelermajerDS. Effect of Lp(a) on the early functional and structural changes of atherosclerosis. Arterioscler Thromb Vasc Biol. 1999;19:990–995.
23.
MikatiMATarabayHKhalilA. Risk factors for development of subclinical hypothyroidism during valproic acid therapy. J Pediatr. 2007;151:178–181.
OsganianSKStampferMJSpiegelmanD. Distribution of and factors associated with serum homocysteine levels in children and adolescent trial for cardiovascular health. J Am Med Assoc. 1999;281:1189–1196.
26.
HuemerMAussererBGraningerG. Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation. Epilepsia. 2005;46:1677–1683.
27.
KiechlSWilleitJ, for the Bruneck Study Group. The natural course of atherosclerosis. Part II: vascular remodeling. Arterioscler Thromb Vasc Biol. 1999;19:1491–1498.
28.
TekgulHDemirNGokbenS. Serum lipid profile in children receiving anti-epileptic drug monotherapy: is it atherogenic?J Pediatr Endocrinol Metab. 2006;19:1151–1155.
29.
ErdemirACulluNYisU. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev. 2009;31:713–716.
30.
GrossoSMostardiniRPicciniBBalestriP. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother. 2009;43:45–50.
31.
KarikasGASchulpisKHBartzeliotouA. Lipids, lipoproteins, apolipoproteins, selected trace elements and minerals in the serum of children on valproic acid monotherapy. Basic Clin Pharmacol Toxicol. 2006;98:599–603.
32.
FranzoniEGovoniMDAddatoS. Total cholesterol, high density lipoprotein cholesterol and triglycerides in children receiving antiepileptic drugs. Epilepsia. 1992;33:932–935.
33.
DemirciogluSSoyluADirikE. Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr Neurol. 2000;23:142–146.
34.
MintzerSSkidmoreCTRankinS. Conversion from enzyme-inducing antiepileptic drugs to topiramate: effects on lipids and C-reactive protein. Epilepsy Res. 2012;98:88–93.
35.
GencBODoganEADoganUGencE. Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment. J Clin Neurosci. 2010;17:1256–1259.
36.
BriggsDEFrenchJA. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf. 2004;3:415–424.
37.
SchwaningerMRinglebPAnneckeA. Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients. J Neurol. 2000;247:687–690.
38.
TümerLSerdarogluAHasanogluA. Plasma homocysteine and lipoprotein (a) levels as risk factors for atherosclerotic vascular disease in epileptic children taking anticonvulsants. Acta Pediatr. 2002;91:923–926.
39.
Castro-GagoMNovo-RodríguezMIGómez-LadoC. Evolution of subclinical hypothyroidism in children treated with antiepileptic drugs. Pediatr Neurol. 2007;37:426–430.
40.
PaknahadZChitsazAZadehHASheklabadiE. Effects of common anti-epileptic drugs on the serum levels of homocysteine and folic acid. Int J Prev Med. 2012;3:S186–S190.
41.
ObisesanTOAliyuMHAdediranAS. Correlates of serum lipoprotein (A) in children and adolescents in the United States. The third National Health Nutrition and Examination Survey (NHANES-III). Lipids Health Dis. 2004;3:29.
42.
GidalBETamuraTHammerAVuongA. Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res. 2005;64:161–166.
43.
VurucuSDemirkayaEKulM. Evaluation of the relationship between C677 T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy. Prog NeuroPsychopharmacol Biol Psychiatry. 2008;32:844–848.
44.
EldeenONAbd EldayemSMShatlaRH. Homocysteine, folic acid and vitamin B12 levels in serum of epileptic children. Egypt J Med Hum Genet. 2012;13:275–280.
45.
VerrottiALausMScardapaneA. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol. 2009;160:81–86.
46.
YehiaMAAhmadSFAbd El-BakeyAO. Antiepileptic drugs and risk of subclinical hypothyroidism. Egypt J Neurol Psychiat Neurosurg. 2012;49:131–136.
47.
Ben-MenachemEAxelsenMJohansonEH. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003;11:556–562.
48.
PeruccaE. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246–255.
49.
VainionpääLKMikkonenKRättyäJ. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine or valproate monotherapy and after withdrawal of medication. Epilepsia. 2004;45:197–203.
50.
SimkoJHoracekJ. Carbamazepine and risk of hypothyroidism. Acta Neurol Scand. 2007;116:317–321.
51.
ShashiASharmaN. Lipid profile abnormalities in hypothyroidism. Int J Sci Nat. 2012;3:354–360.
52.
DuntasLHWartofskyL. Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence?Thyroid. 2007;17:1075–1084.
